Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.
about
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesChallenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsHarnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosisTailored treatment for HIV+ persons with mental illness: the intervention cascadeClinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic reviewExpanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practiceIncidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatmentExpanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients.When to start antiretroviral therapy in resource-limited settings: a human rights analysis.Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014.Community HIV-1 drug resistance is associated with transmitted drug resistanceE138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History StudyTest and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DCHIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United StatesHIV viral load levels and CD4+ cell counts of youth in 14 cities.Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.HIV treatment as prevention: the key to an AIDS-free generation.Progress realized: trends in HIV-1 viral load and CD4 cell count in a tertiary-care center from 1999 through 2011Changing risk behaviours and the HIV epidemic: a mathematical analysis in the context of treatment as prevention.The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco.Prevention and treatment of HIV/AIDS among drug-using populations: a global perspectiveHIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureRates of emergence of HIV drug resistance in resource-limited settings: a systematic review.The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.Towards targeted screening for acute HIV infections in British ColumbiaThe urgency of providing comprehensive and integrated treatment for substance abusers with HIVThe first decade of antiretroviral therapy in Africa.Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice.Switching antiretroviral therapy to minimize metabolic complications.Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men.Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.
P2860
Q24197939-3BB12D3B-0B72-43C6-B60A-7DB5F637A71DQ24234597-B5D56844-4FF6-41A3-9EE8-F78ED6E9FB5FQ24234903-FF13A44B-9DF6-46F8-AAC4-CE17BC609052Q26781511-B0201407-B975-49CD-9BE9-F9E1C1D4819FQ26828443-78C4A70A-3DB6-49FD-9B88-35DFE6572E64Q27013834-7C5D7E7D-E816-414B-A20C-D1F53DB6C15CQ27026742-A2460F3C-B088-43C2-A7EE-2A942B60574EQ28474271-CF1DFDBD-08D8-41FD-B2B7-68B14B7F926AQ28477270-B0B4DC69-CB97-4F88-8025-C32DC4693198Q28487377-B3E06184-0F7C-47F6-A841-4152A8AEC695Q28732123-9155D952-97F6-46C5-B503-819BDF36CE8FQ30975343-935098AF-74BB-4A04-9465-9784756564D8Q33548096-A70DE326-80D7-4119-9684-CFE72F3FB6C8Q33582022-2BA1F73C-358F-4955-8587-5C1C727B5C31Q33601674-532250A7-CD82-47EF-A0CD-5490605DC9BFQ33748960-3BE77764-2D86-46A6-BED5-2470FFF24611Q33873990-CC329ACA-093D-40B3-B5E4-30325770020CQ33951598-F5FBF837-7DC9-4457-9D1A-BE712912B410Q34005333-84627844-FFF3-4E48-BA8C-10A8C1C25832Q34015293-7297E99A-97E3-4AE1-90CA-2589AA6EF2F0Q34117147-D5E3061E-A403-4662-9D5E-DA8BD1117AAAQ34126545-FEEC4B9B-6B1E-430A-95C8-15804367AFF2Q34154129-7844B30F-B9ED-41C1-811D-E354EC932AE4Q34599593-C34D08A0-3CE8-4284-B58E-141AE5BBA723Q34720561-72BCB15A-D948-41B1-8569-6A41FDD82782Q34756819-98DCB280-C375-47CD-B4A4-D194CA8D8CC0Q34780130-0D872221-4FF7-4970-B420-319D4542C11AQ34781706-E6BC4F7D-1668-4025-AFA2-A909460198ADQ34969496-870F1F8C-54C9-49FE-8116-2F8E6BA6FDE8Q35019915-545D6DC8-765B-4CE9-AE30-2DFB3EF9C0E1Q35119311-6936A549-EF6D-452D-A5A6-FC6FB7638721Q35203643-E6A69BAB-EB6B-403F-82F9-3F95A2000A13Q35308404-A454B368-E633-448A-A560-B54A778B8E2FQ35337985-E8BAA4AD-80F6-44EE-AA9E-C2DD861B5027Q35452272-F07536A0-3293-4C7C-AD8A-F45EDAE0EC9CQ35608074-CC95519F-C13B-425C-9FC6-4BA524680A1FQ35881070-77963361-D020-47F9-BC9B-1939FB341E0DQ35949742-B4ED6914-4549-4147-9BA0-8E7660ACB78BQ36158371-203D73B5-A7C0-44A0-A62C-37BBB1B0FF47Q36188421-AC291629-E476-4906-BDD2-666420144DFD
P2860
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Improved virological outcomes ...... e 1 drug resistance detection.
@ast
Improved virological outcomes ...... e 1 drug resistance detection.
@en
Improved virological outcomes ...... e 1 drug resistance detection.
@nl
type
label
Improved virological outcomes ...... e 1 drug resistance detection.
@ast
Improved virological outcomes ...... e 1 drug resistance detection.
@en
Improved virological outcomes ...... e 1 drug resistance detection.
@nl
prefLabel
Improved virological outcomes ...... e 1 drug resistance detection.
@ast
Improved virological outcomes ...... e 1 drug resistance detection.
@en
Improved virological outcomes ...... e 1 drug resistance detection.
@nl
P2093
P2860
P356
P1476
Improved virological outcomes ...... e 1 drug resistance detection.
@en
P2093
Benita Yip
Brian Wynhoven
P Richard Harrigan
Vikram S Gill
Viviane D Lima
P2860
P304
P356
10.1086/648729
P407
P577
2010-01-01T00:00:00Z